How Much Weight Can You Lose on Wegovy? Real Trial Data vs Expectations

Published 12 July 2026  ·  8 min read

"About 15%" is the number most people have heard. It comes from the STEP 1 clinical trial and is technically accurate — for the average participant in that specific study. But clinical trial averages are a starting point for setting expectations, not a target you should hold yourself to. Here's what the full picture looks like, why individual outcomes vary so much, and how to think about your own progress.

The STEP Trials: What They Measured and What They Found

Wegovy's approval was supported by a programme of trials called the STEP (Semaglutide Treatment Effect in People with Obesity) programme. Four main trials produced the core data.

The headline figure — 15% — comes from STEP 1, which is the most often cited because it studied people with obesity but without type 2 diabetes, which is the population most likely to seek Wegovy for weight management.

STEP 2 is worth noting: people with type 2 diabetes lost significantly less weight on average (9.6%). T2D changes how the body responds to GLP-1 medications. If you have T2D, your expected average weight loss with semaglutide is lower — which doesn't mean it won't work, but it's worth calibrating your expectations accordingly.

STEP 3 is interesting because it shows what happens when Wegovy is combined with intensive behavioural intervention — structured counselling, meal plans, physical activity guidance. The average weight loss was 17.4%, suggesting the medication works better in the context of a structured lifestyle programme.

What "Average" Actually Means

In STEP 1, some participants lost 5% of their body weight. Others lost 25% or more. The 14.9% average is a midpoint in a wide distribution. About one-third of STEP 1 participants lost 20% or more of their body weight. About one in seven lost less than 5%.

This variation is real and it's significant. The people who responded well to Wegovy did extraordinarily well by historical standards of obesity pharmacotherapy. The people who responded poorly may have been better served by a different medication (tirzepatide tends to produce higher average weight loss) or by investigating other factors — sleep apnoea, thyroid function, medications that promote weight gain, and so on.

What Drives the Variation?

Individual response to semaglutide is influenced by a complex combination of factors. Some of these are biological — genetics, gut microbiome, baseline insulin sensitivity, hormonal environment — and can't be controlled directly. Others are behavioural and environmental, and those you can work with.

Diet and eating patterns: Wegovy reduces appetite significantly, but it doesn't override food choices. People who eat mostly ultra-processed foods tend to lose less weight than those who shift toward higher-protein, lower-calorie-density diets. The medication makes it easier to eat less; it doesn't change what you eat.

Physical activity: Exercise doesn't drive weight loss as directly as most people expect — you can't out-exercise a poor diet. But resistance training in particular helps preserve lean muscle mass during weight loss, which matters for long-term metabolic health and for how your body looks at a lower weight.

Adherence and dose: Reaching and maintaining the 2.4mg maintenance dose is critical. Most weight loss in the trials happened at maintenance dose. People who couldn't tolerate escalation to 2.4mg tended to lose less weight on average.

Sleep: Poor sleep raises hunger hormones (ghrelin) and reduces satiety hormones. Addressing sleep quality often improves GLP-1 medication outcomes.

How Long Does It Take?

The full effect of Wegovy takes time to materialise. In STEP 1, weight loss continued steadily throughout the 68-week trial, with the steepest decline happening in the first 20–30 weeks and then gradually slowing as participants approached their plateau. Most people hadn't finished losing weight by week 68 — they were still on a downward trend.

In real-world terms: expect early signs within the first four to eight weeks (reduced appetite, early weight movement), meaningful visible loss by weeks 12–20, and ongoing steady loss through months 6–18. Plateaus are normal and don't mean the medication has stopped working.

What About After the First Year?

STEP 4 is the most sobering of the trials. After an initial 20-week period on semaglutide where participants lost around 10.6% of their body weight, half were switched to placebo. Over the following 48 weeks, those who stopped the medication regained about two-thirds of the weight they had lost. Those who continued semaglutide continued to lose.

This tells us that GLP-1 medications are effective while you take them but that the benefit doesn't persist indefinitely after stopping. That's not unlike blood pressure medication, which also needs to be continued to maintain its effect. It does have implications for thinking about these medications as long-term treatments rather than short-term courses.

A Realistic Expectation

If you're starting Wegovy: expect meaningful weight loss, particularly once you've been at the 2.4mg maintenance dose for several months. A 10–20% reduction in body weight is a reasonable target for most people, with some doing significantly better. Pairing the medication with genuine dietary and lifestyle changes gives you the best chance of being in the upper end of that range.

Track your own results and measure yourself against where you started — not against a trial average or anyone else's progress.

Medical disclaimer: Clinical trial data discussed in this article represents average outcomes in specific study populations and should not be interpreted as a prediction of individual results. Weight loss outcomes depend on many individual factors. Always discuss your expectations and progress with your prescriber.